Theravance Biopharma (TBPH) Misses Q1 EPS by 5c, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 8, 2025 4:05 PM EDTYUPELRI® (revefenacin) net sales of $58.3 million, recognized by Viatris, increased 6% versus Q1 20241 TRELEGY net sales of $854M, as reported by GSK, increased 14% versus Q1 20242CYPRESS study open label enrollment nearing completion with final patient expected to be enrolled by late summerQuarter-end cash balance of $131 million, with no debtReaffirming all financial guidance metrics
DUBLIN, May 8, 2025 /PRNewswire/ --... More
